Moclobemide
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Moclobemide: From Anxiety Disorder to Agoraphobia
One-Sentence Summary
Moclobemide is a reversible inhibitor of monoamine oxidase A (MAO-A), originally used for anxiety disorder, neurotic disorder and dysthymic disorder. The TxGNN model predicts it may be effective for agoraphobia (the top-ranked prediction), supported by no registered clinical trials but 10 publications, including 2 randomised controlled trials in panic disorder with agoraphobia. This is a near-label extension of its existing anxiety use rather than a true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Anxiety disorder, neurotic disorder, dysthymic disorder (the Singapore licence record contains no indication text) |
| Predicted New Indication | Agoraphobia |
| TxGNN Prediction Score | 99.43% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled record. Based on known pharmacology, moclobemide is a reversible inhibitor of MAO-A (the compiled data also list MAO-B as a target). This raises serotonin, norepinephrine and dopamine levels. The same monoaminergic mechanism is shared by antidepressants used in panic disorder with agoraphobia.
Agoraphobia usually occurs together with panic disorder, and anxiety disorders are already among moclobemide's original indications. Randomised trials in panic disorder (with or without agoraphobia) support the link. One placebo-controlled trial tested moclobemide, cognitive-behavioural therapy and their combination, and another compared moclobemide with clomipramine. The exact population of the first trial is not stated in its title, so its fit to agoraphobia is inferred.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10448444 | 1999 | RCT | Br J Psychiatry | Placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia |
| 10361962 | 1999 | RCT (active comparator) | Eur Arch Psychiatry Clin Neurosci | Moclobemide 450 mg/day vs clomipramine 150 mg/day in 135 patients with panic disorder, with or without agoraphobia |
| 28867934 | 2017 | Review | Dialogues Clin Neurosci | Guideline- and meta-analysis-based treatment recommendations for anxiety disorders, including panic disorder/agoraphobia |
| 32002937 | 2020 | Review | Adv Exp Med Biol | Psychopharmacological recommendations for anxiety disorders based on guidelines and systematic reviews |
| 7717094 | 1995 | Review | Acta Psychiatr Scand Suppl | Reversible MAO-A inhibitors (including moclobemide) in mental disorders; unequivocal antidepressant activity |
| 8313401 | 1993 | Review | Clin Neuropharmacol | Reversible MAO-A inhibitors in panic disorder; brofaromine vs clomipramine trial |
| 12006898 | 2002 | Review/Model | J Clin Psychopharmacol | Interactive model of therapeutic response in panic disorder, using moclobemide data |
| 16850261 | 2006 | Imaging study | Metab Brain Dis | Citalopram vs moclobemide effects on resting brain perfusion in social anxiety disorder |
| 7954487 | 1994 | Open-label pilot | Clin Neuropharmacol | 35 outpatients with social phobia; improvement in fear and avoidance, good tolerability |
| 7892341 | 1995 | Case report | Psychiatr Prax | Treatment-refractory panic disorder remitted with imipramine, moclobemide and behaviour therapy |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN13093P | MOCLOBEMIDE HEXAL TABLET 150mg | Tablet | Not stated in the licence record |
Safety Considerations
- Drug Interactions: The interaction query returned pharmacological target records only (MAO-A and MAO-B inhibition), not specific drug-drug interaction entries. The literature indicates moclobemide may raise exposure to triptans, and the wider MAO-inhibitor class carries tyramine and serotonergic interaction concerns.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two randomised trials in panic disorder with or without agoraphobia, together with several reviews, support moclobemide in this area. However, there are no registered trials specific to agoraphobia, and moclobemide is already marketed for anxiety disorders, so this is a near-label extension.
To proceed, the following is needed:
- The Singapore package insert warnings and contraindications (currently unavailable, and a blocking gap for safety screening)
- Detailed mechanism of action data
- Confirmation of the agoraphobia-specific population and outcomes in the key RCT (PMID 10448444)
- A guardrail plan for serotonergic drug and tyramine interactions
Other Predicted Indications (Brief Notes)
| Rank | Predicted Indication | Evidence Level | Assessment | |------|------|------|------| | 3 | Neurotic depression | L1 | Placebo-controlled trials and a meta-analysis support efficacy. Effectively on-label (dysthymic/neurotic disorder), so Proceed with Guardrails: monitor tyramine and serotonergic interactions and sexual dysfunction | | 4 | Melancholia | L2 | Evidence addresses depression in general, not the melancholic subtype. RIMAs are often considered less effective than tricyclics in severe depression. Proceed with Guardrails | | 7 | Migraine disorder | L4 | Only small, unclear-design prophylaxis reports; most papers concern triptan interaction hazards. Research Question | | 9 | Obsessive-compulsive disorder | L3 | Only small clinical data; guidelines favour SSRIs and clomipramine. Research Question | | 2, 5, 6, 8, 10 | Benign paroxysmal torticollis of infancy, Keppen-Lubinsky syndrome, vitamin B12-responsive methylmalonic acidemia, migraine with brainstem aura, autosomal dominant slowed nerve conduction velocity | L5 | High model scores only, with no trials, no literature and no plausible mechanism. Hold |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.